Thermo Fisher Scientific, Inc., a prominent American company in the Health Care sector, specializing in Life Sciences Tools & Services, has recently disclosed insider transactions under a Rule 10b‑5‑1 trading plan. The company, listed on the New York Stock Exchange, reported these transactions involving its common stock, executed by its chairman and CEO, Marc N. Casper.
As of August 2026, Marc N. Casper conducted several trades, resulting in a net change that leaves him with approximately 124,000 shares of Thermo Fisher Scientific. Additionally, Casper’s trusts hold 5,000 and 11,300 shares, respectively, indicating substantial indirect holdings. These transactions were disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC) and took place in late August 2026.
Thermo Fisher Scientific, Inc. is renowned for its comprehensive range of products and services, including analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies. These offerings cater to a diverse clientele, including pharmaceutical and biotech companies, hospitals, clinical diagnostic labs, universities, research institutions, and government agencies.
Financially, the company has demonstrated robust performance. As of August 27, 2026, the close price of Thermo Fisher Scientific’s stock was $622.18. The stock has experienced a 52-week high of $647 on August 24, 2026, and a 52-week low of $435.27 on May 17, 2026. The company’s market capitalization stands at approximately $233.2 billion, with a price-to-earnings ratio of 34.11.
No other public announcements or corporate actions have been recorded in conjunction with these insider transactions. For further information on Thermo Fisher Scientific’s products and services, interested parties can visit their official website at www.thermofisher.com .
